EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling

[1]  Jeong-Seok Nam,et al.  EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling , 2014, Cellular and Molecular Life Sciences.

[2]  K. S. Rao,et al.  Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. , 2014, Journal of medicinal chemistry.

[3]  Jeong-Seok Nam,et al.  EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis , 2014, Molecular Cancer Therapeutics.

[4]  D. Griggs,et al.  Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs , 2013, Nature Network Boston.

[5]  D. Schuppan,et al.  Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.

[6]  S. Friedman,et al.  Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.

[7]  R. Samarakoon,et al.  TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. , 2013, Cellular signalling.

[8]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[9]  Akhurst,et al.  Title Targeting the TGFβ signalling pathway in disease , 2012 .

[10]  Y. Sheen,et al.  EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. , 2011, European journal of cancer.

[11]  K. Iwaisako,et al.  The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91phox mediate hepatic fibrosis in mice , 2011, Hepatology.

[12]  D. Schuppan,et al.  Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. , 2011, Gastroenterology.

[13]  M. Bitzer,et al.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. , 2011, Cancer research.

[14]  Scott L. Friedman,et al.  Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.

[15]  K. Iwaisako,et al.  Hepatocytes do not undergo epithelial‐mesenchymal transition in liver fibrosis in mice , 2010, Hepatology.

[16]  M. Bitzer,et al.  Reduced SMAD7 Leads to Overactivation of TGF-b Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-b , 2010 .

[17]  R. Liu,et al.  Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. , 2010, Free radical biology & medicine.

[18]  D. Schuppan,et al.  Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies , 2009, Hepatology.

[19]  R. Derynck,et al.  Differentiation plasticity regulated by TGF-|[beta]| family proteins in development and disease , 2007 .

[20]  R. Derynck,et al.  Differentiation plasticity regulated by TGF-β family proteins in development and disease , 2007, Nature Cell Biology.

[21]  F. Verrecchia,et al.  Transforming growth factor-β and fibrosis , 2007 .

[22]  Shyam Biswal,et al.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.

[23]  F. Verrecchia,et al.  Transforming growth factor-beta and fibrosis. , 2007, World journal of gastroenterology.

[24]  F Verrecchia,et al.  [Cellular and molecular mechanisms of fibrosis]. , 2006, Annales de pathologie.

[25]  James Q. Yin,et al.  Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis , 2006 .

[26]  S. Rhee,et al.  Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. , 2005, Free radical biology & medicine.

[27]  J. Gauthier,et al.  Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis , 2005 .

[28]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[29]  Giulio Gabbiani,et al.  Perspective Article: Tissue repair, contraction, and the myofibroblast , 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[30]  R. Bataller,et al.  Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller , 2018 .

[31]  A. Mallat,et al.  Hepatic fibrosis: molecular mechanisms and drug targets. , 2005, Annual review of pharmacology and toxicology.

[32]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[33]  T. Sawyer.  Novel oncogenic protein kinase inhibitors for cancer therapy. , 2004, Current medicinal chemistry. Anti-cancer agents.

[34]  M. Reiss,et al.  Targeting Endogenous Transforming Growth Factor β Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype 1 , 2004, Cancer Research.

[35]  J. Fallowfield,et al.  Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.

[36]  D. Bigner,et al.  SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. , 2004, Molecular cancer therapeutics.

[37]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  A. Roberts,et al.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.

[39]  S. Basu.  Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. , 2003, Toxicology.

[40]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[41]  S. Kim,et al.  Progression of hepatic stellate cell activation is associated with the level of oxidative stress rather than cytokines during CCl4-induced fibrogenesis. , 2000, Molecules and cells.

[42]  G. Poli.  Pathogenesis of liver fibrosis: role of oxidative stress. , 2000, Molecular aspects of medicine.

[43]  S. Friedman.  Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* , 2000, The Journal of Biological Chemistry.